Project Grant R01CA295672
- Federal Project Grant Award Summary The National Cancer Institute awarded The Jackson Laboratory a $704,636 Project Grant under the Cancer Biology Research program (CFDA 93.396) on May 14, 2026, with an ultimate completion date of April 30, 2031. This award funds fundamental research investigating pre-leukemic hematopoietic stem cell (HSPC) clonal selection by the adaptive immune system, with the objective of identifying immuno-preventative strategies to intercept leukemogenesis at its...
- Federal Project Grant Award Summary The Jackson Laboratory received a $1.89 million Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), effective August 1, 2025, through July 31, 2028. The award funds research entitled "Revealing Spatial Transcriptomic and Proteomic Shifts in Tumor-Infiltrating Immunocytes: Charting a Path to Enhanced Melanoma Therapeutics." This project will be conducted at Jackson...
- Federal Grant Award Summary The National Institute of General Medical Sciences (NIGMS) awarded The Jackson Laboratory a $486,750 Project Grant under the Biomedical Research and Research Training program (CFDA 93.859) on August 15, 2025, with a completion date of July 31, 2030. This five-year award supports the development of a novel computational framework called Multi-Omics-Multi-Organ Sequencing (MOMO-SEQ) for investigating mammalian iron systems biology across multiple organ systems. The...
- Federal Grant Award Summary The Jackson Laboratory received a $1.0 million Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) awarded on May 15, 2025, with completion scheduled for May 14, 2028. This award funds research titled "Uncovering Spatial and Temporal Alterations of Metabolism in the Kidney, Paving the Road to Treatment of Lupus Nephritis," conducted at the organization's Bar Harbor, Maine facility. The...
- Federal Grant Award Summary The Jackson Laboratory received a $932,993 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded June 2, 2026, with completion targeted for May 31, 2031. This research initiative examines trained immunity signatures and reduced vaccine responses in older adults by investigating epigenetic remodeling of hematopoietic stem and progenitor cells (HSPCs). The...
- Federal Project Grant Award Summary The National Cancer Institute awarded a Project Grant of $495,715 to the Sloan-Kettering Institute for Cancer Research under the Cancer Biology Research program (CFDA 93.396) on August 5, 2025, with a completion date of July 31, 2030. This award funds fundamental research to decipher the pathogenesis and therapeutic vulnerabilities in germline RUNX1-mutated acute myeloid leukemia (AML). The research focuses on understanding how germline RUNX1 mutations...
- Federal Grant Award Summary The National Cancer Institute awarded $138,846 to the University Health Network under the Cancer Detection and Diagnosis Research program (CFDA 93.394) for a two-year Project Grant commencing August 1, 2025 and concluding July 31, 2027. The award supports the development of laboratory-generated "wild-like" mouse models designed to enhance the translational relevance of preclinical cancer and immunotherapy research. The primary deliverable involves adapting...
- Federal Grant Award Summary Thomas Jefferson University (Sidney Kimmel Medical College) received a $484,405 Project Grant from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396) effective September 1, 2025, through August 31, 2030. This five-year award supports fundamental cancer biology research investigating NSD2 (Nuclear Set Domain Family Member 2) mutations and their role in driving acute lymphoblastic leukemia (ALL) transformation. The research...
- Federal Grant Award Summary Baylor College of Medicine received a $160,500 Project Grant award from the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396), effective July 10, 2025, with completion targeted for June 30, 2027. The award funds the development and investigation of in vivo murine models to examine the role of caspase-2 in nucleophosmin-mutated acute myeloid leukemia (NPM1C+ AML). The research deliverables include the establishment of transgenic mouse...
- Grant Award Summary The Jackson Laboratory received a $716,579 Project Grant award from the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866) effective December 15, 2025, with completion scheduled for November 30, 2030. The award funds a comprehensive research initiative investigating the genetic mechanisms underlying microglia-mediated synapse loss in Alzheimer's disease. The project employs genetically engineered mouse models and multi-modal genetic...
The National Cancer Institute (NCI) awarded The Jackson Laboratory a $543,984 Project Grant under the Cancer Biology Research program (CFDA 93.396) effective June 1, 2026, through May 31, 2031. This award funds animal studies investigating the role of ZBTB7A in acute myeloid leukemia (AML) differentiation and therapeutic response. The Jackson Laboratory will provide in vivo research services utilizing NSG-SGM3 mice, a specialized immunocompromised mouse model optimized for engrafting primary patient-derived AML xenografts. These services include assessment of leukemia engraftment, disease progression, systemic treatment exposure, and therapeutic response evaluation—outcomes that cannot be adequately modeled through in vitro methods alone. Specifically, The Jackson Laboratory will support two primary research aims: (1) evaluating the effects of ELAVL1/ELAVL4 perturbation on AML biology, and (2) assessing the in vivo delivery efficiency and therapeutic potential of CpG-conjugated antisense oligonucleotides (ASOs) targeting the long ZBTB7A 3' untranslated region isoform on leukemia burden and survival. By leveraging its expertise in mammalian genetics and genetically engineered mouse model development and maintenance, Jackson Laboratory will enable faithful assessment of leukemia growth kinetics and treatment response while preserving the biologic heterogeneity of patient tumor samples—critical capabilities for translating preclinical findings toward improved AML therapeutics.Federal Project Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $544.0k | 6/1/26 |